阿托伐他汀钙联合曲美他嗪对慢性心力衰竭患者心功能的影响
|
摘要
目的:探讨阿托伐他汀钙联合曲美他嗪对慢性心力衰竭患者心功能的影响。方法:选取2015年3月至2018年3月遵义医学院第五附属(珠海)医院收治的慢性心力衰竭患者100例,采用随机数字表法分为对照组和观察组,每组50例。两组患者均给予常规治疗,观察组患者加用阿托伐他汀钙联合曲美他嗪治疗,两组患者的疗程均为6个月。比较两组患者的6 min步行试验距离、治疗前后左心室收缩末期内径(LVEDS)、左心室舒张末期内径(LVEDD)、左心室射血分数(LVEF)及血清N末端B型利钠肽原(NT-proBNP)水平的差异。结果:治疗3、6个月后,两组患者6 min步行试验距离较治疗前明显增加,且观察组患者明显长于对照组,差异均有统计学意义(P<0.05);治疗3、6个月后,两组患者LVEDS、LVEDD水平较治疗前明显降低,LVEF水平明显升高,且观察组患者明显优于对照组,差异均有统计学意义(P<0.05);治疗3、6个月后,两组患者血清NT-proBNP水平较治疗前明显降低,且观察组患者明显低于对照组,差异均有统计学意义(P<0.05)。结论:阿托伐他汀钙联合曲美他嗪能明显改善慢性心力衰竭患者的心功能,临床疗效显著。
OBJECTIVE: To probe into the effects of atorvastatin calcium combined with trimetazidine on cardiac function in patients with chronic heart failure. METHODS: Totally 100 patients with chronic heart failure admitted into the Fifth Affiliated(Zhuhai) Hospital of Zunyi Medical College from Mar. 2015 to Mar. 2018 were extracted to be divided into obervation group and control group via the random number table, with 50 cases in each group. Both groups received the routine treatment, and the observation group was additionally treated with atorvastatin calcium combined with trimetazidine. The course of treatment was 6 months. Differences of the 6-min walking test, left ventricular systolic end diameter(LVEDS), left ventricular diastolic end diameter(LVEDD), left ventricular ejection fraction(LVEF) and serum N-Terminal B natriuretic peptide propeptide(NT-proBNP) levels before and after treatment were compared between two groups. RESULTS: After treatment for 3 and 6 months, the 6-min walking distance of two groups was significantly higher than that before treatment, and the observation group was significantly longer than the control group, with statistically significant difference(P<0.05). After treatment for 3 and 6 months, the LVEDS and LVEDD of two groups were significantly lower than those before treatment, and the LVEF increased significantly, the observation group were significantly better than the control group, and the differences were statistically significant(P<0.05). After treatment for 3 and 6 months, the serum NT-proBNP levels of two groups was significantly lower than that before treatment, and the observation group was significantly lower than the control group, the difference was statistically significant(P<0.05). CONCLUSIONS: Atorvastatin combined with trimetazidine can significantly improve the cardiac function of patients with chronic heart failure, and the clinical efficacy is remarkable.
OBJECTIVE: To probe into the effects of atorvastatin calcium combined with trimetazidine on cardiac function in patients with chronic heart failure. METHODS: Totally 100 patients with chronic heart failure admitted into the Fifth Affiliated(Zhuhai) Hospital of Zunyi Medical College from Mar. 2015 to Mar. 2018 were extracted to be divided into obervation group and control group via the random number table, with 50 cases in each group. Both groups received the routine treatment, and the observation group was additionally treated with atorvastatin calcium combined with trimetazidine. The course of treatment was 6 months. Differences of the 6-min walking test, left ventricular systolic end diameter(LVEDS), left ventricular diastolic end diameter(LVEDD), left ventricular ejection fraction(LVEF) and serum N-Terminal B natriuretic peptide propeptide(NT-proBNP) levels before and after treatment were compared between two groups. RESULTS: After treatment for 3 and 6 months, the 6-min walking distance of two groups was significantly higher than that before treatment, and the observation group was significantly longer than the control group, with statistically significant difference(P<0.05). After treatment for 3 and 6 months, the LVEDS and LVEDD of two groups were significantly lower than those before treatment, and the LVEF increased significantly, the observation group were significantly better than the control group, and the differences were statistically significant(P<0.05). After treatment for 3 and 6 months, the serum NT-proBNP levels of two groups was significantly lower than that before treatment, and the observation group was significantly lower than the control group, the difference was statistically significant(P<0.05). CONCLUSIONS: Atorvastatin combined with trimetazidine can significantly improve the cardiac function of patients with chronic heart failure, and the clinical efficacy is remarkable.
引文
[1] 邱伯雍.慢性心力衰竭流行病学及防治研究进展[J].中华实用诊断与治疗杂志,2017,31(6):619-621.
[2] 秦晓毅,卢新政.2010年NICE慢性心力衰竭诊治指南更新的解读[J].心血管病学进展,2011,32(4):490-492.
[3] 中华医学会心血管病分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,44(2):98-122.
[4] AhmedA,杜媛.一项关于心力衰竭患者纽约心脏协会心功能分级和自然病史终点的倾向匹配研究[J].世界核心医学期刊文摘:心脏病学分册,2007(7):27-28.
[5] 国家卫生计生委合理用药专家委员会,中国药师协会.心力衰竭合理用药指南[J].中国医学前沿杂志:电子版,2016,8(9):23-24.
[6] 苏冠华,孙雨霏,卢永昕.心力衰竭的能量代谢重构及其治疗[J].国际心血管病杂志,2012,39(2):65-67.
[7] 邢作英.慢性心力衰竭流行病学研究现状及其病因[J].中华实用诊断与治疗杂志,2012,26(10):937-938.
[8] 李雁.阿托伐他汀对慢性心力衰竭患者心功能的影响[J].安徽医学,2015,36(7):871-873.
[9] 武智晓,黎明江.阿托伐他汀对心衰患者LVEF影响的Meta分析[J].海南医学,2012,23(1):132-134.
[10] 马强,崔国雄.阿托伐他汀联合曲美他嗪对冠心病患者心功能、炎性因子及血管内皮功能的影响[J].实用临床医药杂志,2016,20(23):5-8.
[11] 田磊.阿托伐他汀与曲美他嗪联合治疗对冠心病患者心功能、炎症因子和内皮功能的影响[J].海南医学院学报,2016,22(14):1489-1492.
[12] 黎洁雯.美托洛尔联合曲美他嗪对冠心病心力衰竭病人心脏功能的影响[J].中西医结合心脑血管病杂志,2016,14(21):2540-2541.
[13] 邹行斌,黄鹤.阿托伐他汀并曲美他嗪对冠心病患者血脂、炎性因子及心功能的疗效[J].心血管康复医学杂志,2016,25(3):276-280.
[14] 杨斌,彭莉,薛燕文等.曲美他嗪治疗冠心病合并心衰的临床循证研究[J].世界临床药物,2012,33(9):544-551.
[15] 李玉子,金恩泽,关立克.曲美他嗪对慢性心力衰竭患者血浆脑钠肽水平及心功能的影响[J].临床心血管病杂志,2007,23(11):879-880.
[2] 秦晓毅,卢新政.2010年NICE慢性心力衰竭诊治指南更新的解读[J].心血管病学进展,2011,32(4):490-492.
[3] 中华医学会心血管病分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,44(2):98-122.
[4] AhmedA,杜媛.一项关于心力衰竭患者纽约心脏协会心功能分级和自然病史终点的倾向匹配研究[J].世界核心医学期刊文摘:心脏病学分册,2007(7):27-28.
[5] 国家卫生计生委合理用药专家委员会,中国药师协会.心力衰竭合理用药指南[J].中国医学前沿杂志:电子版,2016,8(9):23-24.
[6] 苏冠华,孙雨霏,卢永昕.心力衰竭的能量代谢重构及其治疗[J].国际心血管病杂志,2012,39(2):65-67.
[7] 邢作英.慢性心力衰竭流行病学研究现状及其病因[J].中华实用诊断与治疗杂志,2012,26(10):937-938.
[8] 李雁.阿托伐他汀对慢性心力衰竭患者心功能的影响[J].安徽医学,2015,36(7):871-873.
[9] 武智晓,黎明江.阿托伐他汀对心衰患者LVEF影响的Meta分析[J].海南医学,2012,23(1):132-134.
[10] 马强,崔国雄.阿托伐他汀联合曲美他嗪对冠心病患者心功能、炎性因子及血管内皮功能的影响[J].实用临床医药杂志,2016,20(23):5-8.
[11] 田磊.阿托伐他汀与曲美他嗪联合治疗对冠心病患者心功能、炎症因子和内皮功能的影响[J].海南医学院学报,2016,22(14):1489-1492.
[12] 黎洁雯.美托洛尔联合曲美他嗪对冠心病心力衰竭病人心脏功能的影响[J].中西医结合心脑血管病杂志,2016,14(21):2540-2541.
[13] 邹行斌,黄鹤.阿托伐他汀并曲美他嗪对冠心病患者血脂、炎性因子及心功能的疗效[J].心血管康复医学杂志,2016,25(3):276-280.
[14] 杨斌,彭莉,薛燕文等.曲美他嗪治疗冠心病合并心衰的临床循证研究[J].世界临床药物,2012,33(9):544-551.
[15] 李玉子,金恩泽,关立克.曲美他嗪对慢性心力衰竭患者血浆脑钠肽水平及心功能的影响[J].临床心血管病杂志,2007,23(11):879-880.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |